Viatris enhanced access to medicines for treating COVID-19 in patients with mild/moderate as well as severe representations of the disease. We obtained a voluntary license from Gilead and MSD for manufacturing Remdesivir and Molnupiravir respectively. Viatris closely collaborated with its partners, regulatory authorities and various ministries to expedite supplies of these products, in light of the emergency due to the pandemic

We partnered with the Institute of Liver and Biliary Sciences in India for the “Healthy Liver, Healthy Delhi” initiative to create awareness and facilitate early screening and detection of hepatitis B and C and screening for liver health. To date, more than 30,000 people have received free screenings through the program

Viatris is working with Unitaid for making available affordable HIV self-test kits. An agreement with Unitaid resulted in a 50% decrease in the price of blood-based HIV self-testing, significantly expanding the market and providing more options for the remaining countries. The new test will cost less than $2 in 135 countries

Viatris has joined hands with Unitaid for providing access to pediatric dispersible formulation of Dolutegravir (DTG), targeted at saving children lives from HIV. The 10 mg strawberry flavoured DTG tablet has resulted in the prevention of premature deaths in low- and middle-income countries. The agreement also lowers the cost significantly from $480 per child to less than $120

Our collaboration with Clinton Health Access Initiative dates back to 2009 when we worked together to increase patient uptake, including TDF volumes for first line in Zambia as part of Unitaid's programme to reduce second-line ARV prices. The collaboration aims to accelerate development and introduce DTG to HIV-positive children

Viatris is partnering with the Bill and Melinda Gates Foundation to increase HIV treatment access in low- and lower-middle-income countries. The collaboration grants access to TLD – DTG Volume Guarantee in addition to the ARV & Oral Contraceptive FDC Product Development along with the Children’s Investment Fund Foundation

Viatris has partnered with the TB Alliance to increase access to the molecule Pretomanid as part of a three-drug tuberculosis regimen worldwide